Skip to main content
SpringerLink
Log in

Palivizumab: preferred agent for prevention of RSV infection in high risk infants

  • New drugs and disease management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Meissner HC, Welliver RC, Chartrand SA, et al. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion. Pediatr Infect Dis J 1999 Mar; 18(3): 223–31

    Article  PubMed  CAS  Google Scholar 

  2. Scott LJ, Lamb HM. Palivizumab. Drugs 1999 Aug; 59(2): 305–11

    Article  Google Scholar 

  3. American Academy of Pediatrics Committee on Infectious Disease and Committee on Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 1998; 102: 1211–1216

    Article  Google Scholar 

  4. Robinson RF, Nahata MC. Respiratory syncytial virus (RSV) immune globulin and palivizumab for prevention of RSV infection. Am J Health-Syst Pharm 2000 Feb 1; 57: 259–64

    PubMed  CAS  Google Scholar 

  5. Medlmmune Inc. Synagis™ (palivizumab) package insert. 1998 Jun 19

  6. Medlmmune Inc. RespiGam™ (respiratory syncytial virus immune globulin intravenous (human) [RSV-IGIV]) package insert. 1996 Mar

  7. Red book. Montvale (NJ): Medical Economics Company, 1999

  8. British National Formulary No. 39. London: The Pharmaceutical Press, 2000 Mar; 297

  9. IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998 Sep; 102 (Part 1): 531–37

    Article  Google Scholar 

  10. Marchetti A, Lau H, Magar R, et al. Expected economic impact of respiratory syncytial virus (RSV) prophylaxis [abstract no. 1592]. Pediatr Res 1999 Apr; 45 (Part 2): 270A

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Palivizumab: preferred agent for prevention of RSV infection in high risk infants. Drugs Ther. Perspect 16, 1–5 (2000). https://doi.org/10.2165/00042310-200016020-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200016020-00001

Keywords

Search

Navigation